Analysts Give QuidelOrtho Co. a Consensus Recommendation of “Moderate Buy”

Trending News 🌥️

QUIDELORTHO ($NASDAQ:QDEL): Analysts have given QuidelOrtho Co. a consensus recommendation of “Moderate Buy”, resulting in an average rating of the same. QuidelOrtho Co. is a leading provider of orthopedic products and services, offering a broad range of solutions to meet the needs of its customers. They specialize in providing advanced orthopedic products and services to the healthcare industry and consumers. Their innovative product line includes prosthetics, orthotics, braces and supports, foot care products, and 3D printing services.

Their services are delivered through a network of licensed orthopedic professionals and specialty stores across the United States. With a history of success and a commitment to quality, QuidelOrtho Co. is an excellent choice for investors looking for steady long-term growth.

Share Price

On Tuesday, QUIDELORTHO CORP‘s stock opened at $91.9 and closed at $91.4, representing a decrease of 0.6% from its previous closing price of 92.0. The stock has seen a decrease in price over the last few days, but analysts are still recommending moderate buy ratings. This could indicate that they still perceive the company to have potential for growth in the future. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Quidelortho Corp. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Quidelortho Corp. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Quidelortho Corp. More…

Key Ratios Snapshot

Some of the financial key ratios for Quidelortho Corp are shown below. More…

Analysis

At GoodWhale, we are committed to helping our customers make informed decisions about their investments. We understand that it is essential to analyze the financials of any potential investment, and we have all the tools you need to help you make the best decision for your portfolio. We have analyzed QUIDELORTHO CORP‘s financials through GoodWhale and our Risk Rating has determined that it is a high risk investment in terms of financial and business aspects. Through our analysis, we have also detected two risk warnings in the income sheet and balance sheet. If you would like to check out our assessment, please register on goodwhale.com. We are confident that our analysis tools will provide you with the insight you need to make the right investing decisions. Let us help you maximize your returns and minimize your risks! More…

Peers

Quidel Corporation is a leading provider of diagnostic healthcare solutions serving both the professional and consumer markets. The company manufactures and sells a broad range of diagnostic products, including immunoassays, molecular diagnostics, and infectious disease tests. Quidel’s products are used in hospitals, physician offices, clinics, and commercial laboratories, as well as at-home for self-testing. Quidel has a strong portfolio of products and a long history of providing high-quality diagnostics.

However, the company faces competition from a number of other companies, including LifePoint Inc, Bloom Health Partners Inc, and Talis Biomedical Corp.

– LifePoint Inc ($OTCPK:LFPI)

LifePoint Inc is a company that provides healthcare services. It has a market cap of 10.21k as of 2022 and a Return on Equity of 8.83%. The company has a strong ROE, which indicates that it is efficient in using its assets to generate profits. The company is doing well financially and is expected to continue to grow in the future.

– Bloom Health Partners Inc ($OTCPK:BLMHF)

The company’s market cap is 2.86M as of 2022. The company’s ROE is 26.8%. The company’s main products and services are health insurance, health care, and benefits administration. Health insurance coverage is provided to individuals, families, and businesses through a variety of plans. Health care services are delivered through a network of providers. Benefits administration services are provided to employers and employees.

– Talis Biomedical Corp ($NASDAQ:TLIS)

Talis Biomedical Corp is a medical technology company that develops and commercializes products based on its proprietary technology Platform for the early detection of infectious diseases. The Platform is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are based on its proprietary platform technology, which is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are intended for use in a variety of settings, including hospital emergency departments, primary care offices, and home health settings. Talis Biomedical’s products are currently in development and have not been cleared for commercial sale by the U.S. Food and Drug Administration.

Summary

QUIDELORTHO CORP has been receiving an overall favorable investment outlook with seven different firms giving it the consensus recommendation of “Moderate Buy”. Analysts have given an average rating of “Moderate Buy” to the company, indicating that it is considered to be a relatively safe and profitable investment. Despite some risks, analysts believe that investors can expect to earn returns from QUIDELORTHO CORP in the foreseeable future. The company’s current financials are stable and consistent, and it is a solid choice for investors looking for a safe and consistent return on their investments.